Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Tardive Dyskinesia Therapeutics Market

Tardive Dyskinesia Therapeutics Market Share

Report ID: GMI9586
Published Date: May 2024
Report Format: PDF

Download Free Sample

Tardive Dyskinesia Therapeutics Market Share

The competitive landscape of the market is characterized by the presence of established companies that manufacture advanced tardive dyskinesia therapeutics products vying for market share. Key players are engaging in strategic initiatives such as collaboration, product launch, investment, and partnerships to strengthen their product portfolio. The companies are actively adopting a multi-pronged approaches to address the rising demand for tardive dyskinesia therapeutics.

Tardive Dyskinesia Therapeutics Market Companies

The company profile section includes both companies that have commercial drug available in market as well as those that are into clinical phase development. Prominent players operating in the tardive dyskinesia therapeutics industry are as mentioned below:

H. Lundbeck A/S
Luye Pharma Group
Mitsubishi Tanabe Pharma Corporation
Neurocrine Biosciences Inc.
SteriMax Inc.
SOM Biotech
Teva Neuroscience, Inc.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global tardive dyskinesia therapeutics market size was valued at USD 3.1 billion in 2023 and will grow at 7.1% CAGR during 2024-2032, driven by the increasing prevalence of tardive dyskinesia.

The valbenazine drug type segment in the market recorded USD 1.6 billion in 2023 and will grow rapidly through 2032, as the drug has demonstrated significant efficacy in reducing the symptoms of tardive dyskinesia in clinical trials.

North America secured 44.2% of the tardive dyskinesia therapeutics market share in 2023 and will expand at a steady pace through 2032, owing to the availability of well-established healthcare infrastructure and access to medical facilities.

H. Lundbeck A/S, Luye Pharma Group, Mitsubishi Tanabe Pharma Corporation, Neurocrine Biosciences Inc., SteriMax Inc., SOM Biotech, and Teva Neuroscience, Inc. among others.